CLASS ACTION UPDATE for ADMS, GDOT and EXC: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

NEW YORK, NY / ACCESSWIRE / January 2, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

ADMS Shareholders Click Here: https://www.zlk.com/pslra-1/adamas-pharmaceuticals-inc-loss-form?prid=5131&wire=1
GDOT Shareholders Click Here: https://www.zlk.com/pslra-1/green-dot-corporation-loss-form?prid=5131&wire=1
EXC Shareholders Click Here: https://www.zlk.com/pslra-1/exelon-corporation-loss-form?prid=5131&wire=1

* ADDITIONAL INFORMATION BELOW *

Adamas Pharmaceuticals, Inc. (NASDAQGM:ADMS)

ADMS Lawsuit on behalf of: investors who purchased August 8, 2017 – September 30, 2019
Lead Plaintiff Deadline : February 10, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/adamas-pharmaceuticals-inc-loss-form?prid=5131&wire=1

According to the filed complaint, during the class period, Adamas Pharmaceuticals, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) health insurers were excluding Adamas's primary product, GOCOVRI, from their prescription formularies or requiring patients to use "step therapy" – i.e., making patients try immediate-release amantadine prior to covering GOCOVRI; (2) the rapid increase in physicians prescribing GOCOVRI during the Class Period was not due to its efficacy; and (3) as a result of the foregoing, the Company's financial statements about Adamas's business, operations, and prospects were materially false and misleading at all relevant times.

Green Dot Corporation (NYSE:GDOT)

GDOT Lawsuit on behalf of: investors who purchased May 9, 2018 – November 7, 2019
Lead Plaintiff Deadline : February 17, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/green-dot-corporation-loss-form?prid=5131&wire=1

According to the filed complaint, during the class period, Green Dot Corporation made materially false and/or misleading statements and/or failed to disclose that: (1) Green Dot's strategy to attract "high-value" long-term customers was at the expense of "one and done" customers; (2) Green Dot's "one and done" customers represented a significant source of revenues in its legacy segment; (3) consequently, Green Dot's strategy was self-sabotaging; and (4) as a result of the foregoing, Defendants' statements about its business and operations were materially false and misleading at all relevant times.

Exelon Corporation (NYSE:EXC)

EXC Lawsuit on behalf of: investors who purchased February 9, 2019 – November 1, 2019
Lead Plaintiff Deadline : February 14, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/exelon-corporation-loss-form?prid=5131&wire=1

According to the filed complaint, during the class period, Exelon Corporation made materially false and/or misleading statements and/or failed to disclose that: (i) Exelon and/or its employees were engaged in unlawful lobbying activities; (ii) the foregoing increased the risk of a criminal investigation into Exelon; (iii) Exelon subsidiary Commonwealth Edison's revenues were in part the product of unlawful conduct and thus unsustainable; and (iv) that, as a result, the Company's public statements were materially false and misleading at all relevant times.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 571845